日本新冠神藥又沒通過審批 鹽野義股價大跌 10%

華爾街見聞
2022.07.21 00:38

鹽野義製藥公司股價大跌 10%，此前日本厚生勞動省專門小組第二次暫緩批准其新冠口服藥 Xocova。

鹽野義製藥公司股價大跌 10%，此前日本厚生勞動省專門小組第二次暫緩批准其新冠口服藥 Xocova。

Source: 華爾街見聞 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.